Skip to content

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again

      1. United States/
      2. Neuroscience

      Neuroscience

      Mood - Treatment Resistant Depression - Major Depressive Disorder with inadequate response to 2 or more antidepressants

      Areas of Interest:

      • Major Depressive Disorder (MDD) journey to Treatment Resistant Depression (TRD)
      • TRD: early patient identification & treatment initiation
      • Primary care provider’s role in the early identification & treatment of TRD
      • Mechanistic rationale to pharmacological treatment approaches
      • Algorithmic treatment approaches in TRD including interventional psychiatry treatments
      • Early use of new antidepressants in TRD
      • Strategies for preventing relapse in TRD, and the impact of relapse prevention
      • Value of innovative treatments from the patient & societal perspective
      • Impact MDD & TRD in minoritized communities and populations

      Mood – Targeting Novel Pathways In Depression

      Areas of Interest:

      • Clinical correlates between unresolved, residual symptoms of Major Depressive Disorder (MDD) and underlying pathophysiology not addressed with current Standard of Care treatments
      • Early use of adjunctive strategies in the treatment of MDD in specialty and primary care setting
      • The role of Nurse Practitioners, Physician Assistants and Primary Care providers in assessment, diagnosis and management of MDD
      • Clinical and biological underpinnings of anhedonia in MDD
      • The neurobiology and neurocircuitry of motivation and reward
      • Best practices in the assessment and diagnosis of anhedonia in MDD patients
      • Clinical and neurobiological underpinnings of insomnia in MDD
      • The role of orexin system in depression
      • Clinical, humanistic and economic impact of anhedonia and/or insomnia symptoms in patients with MDD
      • Diversity, Equity and Inclusion considerations in assessment, diagnosis and management of MDD (including specific symptoms of anhedonia and/or insomnia)
      • Experience of MDD with anhedonia or insomnia by diverse patient segments

      Schizophrenia - Adults with Schizophrenia

      Areas of Interest:

      • Earlier adoption of long-acting injectable antipsychotics (LAI)
      • Clinical stability & persistency through advancing patients to a longer dosing interval
      • Switching oral antipsychotics to long-acting injectable antipsychotics
      • Effects and dynamics of a therapeutic alliance between the treatment team (incl nurse practitioners & pharmacists) and patient/caregiver to co-create a treatment plan early in the patient journey helping patients progress through their treatment plan
      • Patient & caregiver preferences in LAI utilization
      • Patterns of antipsychotic LAI utilization in minoritized communities and populations (including social determinants of health)
      • Competency models assessing injection techniques in the administration of atypical antipsychotic LAIs
      • Antipsychotic LAI transition of care models (inpatient to outpatient)
      • Champion the destigmatization of schizophrenia to encourage compassion and acceptance

      Learners of Interest

      • Nurse Practitioners
      • Early-in-Career
      • Psychiatrists
      • Primary Care
      • Patient
      • Caregiver / Care Team
      • Physician Assistants
      • Pharmacists
      • Payer
      • Advocacy Partners

      Certificate Of Separation

      Please click here to view the certificate of separation
      Click here to submit an Independent Medical Education Grant